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Background: Uncoupling protein 2 (UCP2) was reported to be involved in lipid metabolism through regulating the
production of superoxide anion. However, the role of UCP2 in hepatocytes steatosis has not been determined. We
hypothesized that UCP2 might regulate hepatic steatosis via suppressing oxidative stress.
Results: We tested this hypothesis in an in vitro model of hepatocytic steatosis in HepG2 cell lines induced by
palmitic acid (PA). We found that treatment with PA induced an obvious lipid accumulation in HepG2 cells and a
significant increase in intracellular triglyceride content. Moreover, the specific inhibition of UCP2 by genipin
remarkably exacerbated PA-induced hepatocytes steatosis. Interestingly, the PA-induced superoxide overproduction
can also be enhanced by incubation with genipin. In addition, administration with the antioxidant tempol
abolished genipin-induced increase in intracellular lipid deposition. We further found that genipin significantly
increased the protein expression of fatty acid translocase (FAT)/CD36.
Conclusions: These findings suggest that UCP2 plays a protective role in PA-induced hepatocytic steatosis through
ameliorating oxidative stress.Background
Hepatic steatosis is an important process in the develop-
ment of nonalcoholic fatty liver disease that is a major
component of metabolic syndrome and a significant risk
factor of cardiovascular disease [1]. The accumulation of
excess neutral fat within hepatocytes is closely related to
obesity and overweight [2], suggesting hepatic steatosis
mostly results from metabolic disturbance of lipids [3].
It was reported that increased level of free fatty acid
(FA) is associated with the onset of fatty liver disease
and hepatic steatosis [4]. However, the molecular mech-
anism underlying FA-induced hepatic fat deposition
remains to be determined.
Uncoupling protein 2 (UCP2) belongs to the mito-
chondrial carrier family and has been thought to be a
metabolic sensor coupling excess FA to lipotoxity [5].
Not only the plasma FA levels are accompanied by the
increased UCP2 expression but also the FA can stimu-
late the activity of the promoter regions of UCP2 gene* Correspondence: yongjiany@yahoo.cn
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reproduction in any medium, provided the or[6]. Moreover, the UCP2 is suggested to promote mito-
chondrial FA oxidation while limiting mitochondrial ca-
tabolism of pyruvate [7]. These findings indicate that
UCP2 might be involved in the development of FA-
induced hepatic steatosis.
Attenuation of hepatic oxidative stress inhibits fat
deposition, indicating that reactive oxygen species
(ROS) might play a central role in the development of
hepatic steatosis [8]. UCP2 has been linked to
mitochondria-derived ROS production. The previous
studies have demonstrated that UCP2 ablation can en-
hance the oxidative stress though decreasing the pro-
ton leak [9]. In addition, ROS is generated during the
metabolism of free FA in mitochondria [10]. Thus,
UCP2 might be involved in hepatic steatosis via regu-
lating ROS production in the process of excess FA oxi-
dation. As UCP2 interacts to the FA translocase
(FAT)/CD36, the uptake of FA might also be regulated
by UCP2 [11].
Therefore, we hypothesized that UCP2 might regulate
hepatic steatosis though a ROS-dependent pathway. In
the present study, we present a cellular model of hepatic
steatosis induced by palmitic acid (PA). We report that
inhibition of UCP2 by genipin increases ROS production. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PA. We also found that genipin-mediated lipid depos-
ition is linked to the upregulation of FAT/CD36.
Results
Inhibition of UCP2 enhances PA-induced hepatic steatosis
Intracellular lipid accumulation was examined using Oil
Red O staining. Treating cultured hepatocytes with PA
(250 μmol/L) medium for 24 h resulted in steatosis; in
contrast, little lipid droplet was found in the untreated
cells (Figure 1A). When cultured hepatocytes were incu-
bated with PA plus UCP2 inhibitor genipin (5 μmol/L),
the cellular lipid inclusions were significantly increased
compared with cells treated with PA alone (Figure 1A).
Intracellular triglyceride level was significantly increased
from control by treatment for 24 h with PA (p < 0.01,A 
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Figure 1 Genipin enhances palmitic acid-induced hepatic steatosis. (A
palmitic acid (PA, 250 μmol/L) and PA plus genipin (5 μmol/L) are shown b
normalized to cellular protein content in HepG2 was determined. Data are
group, ## p < 0.01 compared with the cells treated with PA. PA, palmitic acFigure 1B) and was further elevated by incubating with
genipin (p < 0.01, Figure 1B).
Inhibition of UCP2 enhances PA-induced oxidative stress
Superoxide anion production in hepatocyte was assessed
by dihydroethidium (DHE) staining. We found that DHE
fluorescence was significantly higher in PA-treated cells
than untreated ones (Figure 2A, B and D). Additionally,
DHE fluorescence in hepatocyte treated with PA plus
genipin was markedly higher than PA-treated cells
(Figure 2B, C and D).
Antioxidant abolishes genipin-induced hepatic steatosis
To confirm the central role of oxidative stress in UCP2
inhibition-mediated enhancement of lipid deposition in
hepatocytes, the antioxidant tempol was applied. We found100×
400× 






) Neutral fat accumulations after 24 h of exposure to control medium,
y staining of HepG2 cells with Oil-Red O. (B) Triglyceride level

























Figure 2 Genipin enhances palmitic acid-induced superoxide production. Intracellular superoxide anion was detected by DHE staining.
HepG2 cells were exposed to control medium (A), palmitic acid (PA, 250 μmol/L) (B) and PA plus genipin (5 μmol/L) (C) for 24 h. (D) Summarized
data showing the average fluorescence intensity in cells from each group. Data are means ± SEM from six individual experiments. ** p < 0.01
compared with the control group, ## p < 0.01 compared with the cells treated with PA. PA, palmitic acid; DHE, dihydroethidium.
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genipin-induced further increase in intracellular lipid de-
position (p < 0.05, Figure 3A, B, C and D).
Inhibition of UCP2 upregurates FAT/CD36
Treatment with PA significantly increased the protein
expressions of UCP2 and FAT/CD36 in cultured hepato-
cytes (p < 0.01, Figure 4A and B). Surprisingly, inhibition
of UCP2-mediated proton leak with genipin further
increased the expression levels of UCP2 and FAT/CD36
(p < 0.05 or p < 0.01, Figure 4A and B).
Discussion
In this study, we assessed the role of UCP2 in regulat-
ing ROS production in cultured hepatocytes under the
condition of FA treatment and established a critical
role of UCP2 in the pathogenesis of hepatic steatosis.
We showed that nutrient excess in the form of high
PA medium resulted in a rapid development of hepatic
steatosis that was enhanced by inhibiting UCP2 withgenipin. We also demonstrated that PA caused produc-
tion of superoxide was enhanced by genipin, while
antioxidant tempol blocked genipin-mediated steatosis.
In addition, we found that protein expressions of UCP2
and FAT/CD36 were significantly upregulated by both
PA and genipin.
The UCP2 protein expression has been linked to the
occurrence of nonalcoholic fatty liver disease [12]. The
expression level of UCP2 in normal hepatocyte is very
low but can be significantly upregulated under the obese
condition [13]. Several studies have demonstrated that
hepatic steatosis is associated with increased expression
of UCP2 expression [14]. However, the exact role of
UCP2 in the development of hepatic lipid deposition has
not been determined. The present study shows that in-
hibition of UCP2 accelerates hepatic steatosis, indicating
that UCP2 might play a compensatory protective role in
PA-induced hepatic fat deposition. This finding suggests
that the drugs upregulating UCP2 might become a novel






























Figure 3 Tempol blocks genipin-mediated hepatic steatosis. Neutral fat accumulations after 24 h of exposure to palmitic acid (PA, 250 μmol/L)
(A), PA plus genipin (5 μmol/L) (B) and PA plus genipin and tempol (1 mmol/L) (C) are shown by staining of HepG2 cells with Oil-Red O. (D) Triglyceride
level normalized to cellular protein content in HepG2 was determined. Data are expressed as mean ± SEM. ** p < 0.01 compared with the PA group,
# p < 0.05 compared with the cells treated with PA plus genipin. PA, palmitic acid; T, tempol.
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plays an important role in the development of hepatic
steatosis. UCP2, a well-established uncoupling protein,
has been viewed as an inhibitor of mitochondrial ROS
production [15]. The present study demonstrates that
the tempol, a well-known antioxidant, blocks UCP2 in-
hibition mediated hepatic steatosis. This finding suggests
that UCP2 inhibition-caused liver fat deposition is
dependent on the overproduction of superoxide.
UCP2 has been implicated in physiological and patho-
logical processes related to lipid metabolism, especially
in the uptake and oxidation of free FA [16,17]. The
enzymes responsible for FA metabolism, such as peroxi-
some proliferator-activated receptor α and FAT/CD36,
were linked to UCP2 [18]. The present study found that
UCP2 inhibition-associated lipid deposition is related to
the upregulation of FAT/CD36, indicating the uptake of
PA by hepatocyte is increased. The genipin-induced
upregulation of UCP2 might be a compensatory effect.Conclusions
In conclusion, the present results demonstrate that
UCP2 plays a protective role in free FA-induced hepatic
steatosis. Moreover, the UCP2-mediated lipid deposition
is attributed to the production of superoxide. The
present findings may contribute to the insights into the
clinical prevention and management of nonalcoholic
fatty liver disease.Methods
Cell culture and treatment
HepG2 cells were obtained from the Shanghai Institute
of Cell Biology (Shanghai, China). Cells were grown in
Dulbecco’s modified eagle’s medium (DMEM; Invitrogen
Co., Carlsbad, California, USA) with 10% FBS in the
presence of 100 U/mL penicillin and 100 μg/mL strepto-
mycin and maintained at 37°C in a humidified atmos-

















































Figure 4 Genipin upregulates UCP2 and FAT/CD36. (A) Western blot analysis of UCP2 and FAT/CD36 expressions. The protein was isolated
from the HepG2 cells after 24 h of exposure to control medium, palmitic acid (PA, 250 μmol/L) and PA plus genipin (5 μmol/L). Equal protein
loading was confirmed using β-actin antibody. (B) Target proteins/β-actin is shown in the bar graph. ** p < 0.01 vs. control group, # p < 0.05,
## p < 0.01 vs. PA group (n = 4).
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Cultured HepG2 cell were plated on cover slides in six-
well plates and maintained in culture media until the
cells reached 95% confluence. Experiment 1: The cells
were incubated for 24 h with control medium, PA
medium (addition of 250 μmol/L PA) and PA plus geni-
pin (addition of 5 μmol/L genipin) supplemented with
identical glucose and serum concentrations. This PA
concentration was used because it has been successfully
used in the previous studies. After that, the cells were
washed with phosphate-buffered saline, fixed with 4%
paraformaldehyde, and stained with Oil Red O, which
detects neutral lipids such as cholesteryl esters and trigly-
ceride [19]. Intracellular triglyceride was detected. Ex-
periment 2: The cells were divided into three groups: PA
(treated with 250 μmol/L of PA), PA + genipin (treated
with 250 μmol/L of OA plus 5 μmol/L of genipin) and
PA + genipin + tempol (treated with 250 μmol/L of OA,
5 μmol/L of genipin and 1 mmol/L of tempol). After in-
cubation for 24 h, Oil Red O staining of the cells was per-
formed, and the intracellular triglyceride was measured.The cells were collected for the detection of UCP2 and
FAT/CD36 expressions.
Dihydroethidium assay
To assess superoxide production, the HepG2 cells were
cultured and treated as above. The medium was
removed, and the cells were rinsed twice with PBS. After
that, the cells were incubated in the dark with dihy-
droethidium (DHE; Sigma-Aldrich, St Louis, MO)
diluted in Krebs (40 μmol/l) for 30 min at 37°C followed
by a 15 min wash in DHE-free Krebs. To quantitate the
DHE fluorescence, the glass slides were placed under the
Leica DM LB2 Fluorescent Microscope (Leica, Wetzlar,
Germany) outfitted with a rhodamine filter set [10].
Western blotting
Cell lysate was prepared by lysing the cells with buffer con-
taining 1% Triton X-100, 150 mM NaCl, 1 mM EDTA,
2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate,
1 mM Na3VO4, 1 μg/mL leupeptin, 1 μg/mL aprotinin,
and 20 mM Tris (pH 7.5). Protein concentration was
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boratories, USA). Lysate was electrophoretically transferred
onto a nitrocellulose membrane and immunoblotted with
rabbit anti-UCP2 and FAT/CD36 IgG (1:500 dilution,
Sigma-Aldrich Co., USA). The blots were incubated with a
horseradish peroxidase-conjugated secondary antibody
(1:1000 dilution, Santa Cruz Biotechnology, USA), and the
bound antibody was visualized using a colored reaction.
The relative band intensity was quantified by the use of
Quantity One software (Bio-Rad). Equal loading of protein
was confirmed by measuring β-actin expression [20].
Statistical analysis
Data are presented as mean ± SEM. Comparisons between
groups were determined by one-way ANOVA with a post
hoc Student’s t-test (SPSS Inc., Chicago, IL). Probabilities
of p < 0.05 were considered statistically significant.
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